• Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
Jupiter Orphan Therapeutics
  • Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors

JOT107

What is MELAS Syndrome?

  • Largest prevalence and patient population of the three indications currently being pursued
  • Pursuit of MELAS Syndrome is based on several pre-clinical studies demonstrating resveratrol significantly increasing mitochondrial activity, which is the key issue to treating the disease
  • JOTROL™​ is expected to be effective in other mitochondrial diseases, creating a significant platform product
MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke, Syndrome is a progressive neurodegenerative disorder. Signs and symptoms can begin at any age however, they most often appear in childhood following a period of normal development. Symptoms include seizures, loss of appetite, weakness and pain as well as recurrent headaches. MELAS Syndrome results in stroke and dementia. It is prevalent in approx. 1 out of every 8,000 people in the U.S.A. No current treatment is available for MELAS Syndrome
Picture
Proudly powered by Weebly
  • Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors